CLEVELAND, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 25,000,000 shares of its common stock, par value $0.01 per share. All 25,000,000 shares are being offered for sale by certain
Q2 2024 net revenues of $277 million increased 8%, compared to Q2 2023 Q2 2024 net income of $9 million or $0.03 per diluted share, compared to net income of $24 million or $0.08 per diluted share in Q2 2023 Q2 2024 Adjusted EBITDA ( 1 ) of $137 million increased 7%, compared to Q2 2023 Q2 2024
CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Christopher Simon as a new
CLEVELAND, July 22, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the
CLEVELAND, May 30, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced that its direct
Q1 2024 net revenues increased 12.5% to $248 million, compared to Q1 2023 Q1 2024 net income of $6 million or $0.02 per diluted share, comp ared to net income of $3 million or $0.01 per diluted share in Q1 2023 Q1 2024 Adjusted EBITDA ( 1 ) increased 13.7% to $112 million, compared to Q1 2023 Q1
CLEVELAND, April 11, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the
CLEVELAND, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the pricing of its secondary offering (the “Offering”) of 25,000,000 shares of its common stock, par value $0.01 per share, at a price to the public of $14.75 per share.
CLEVELAND, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 25,000,000 shares of its common stock, par value $0.01 per share. All 25,000,000 shares are being offered for sale by selling stockholders, which
2023 net revenues increased 4.5% to $1.05 billion , compared to 2022 2023 net income of $51 million or $0.18 per diluted share 2023 Adjusted EBITDA (1) increased 4.3% to $528 million 2023 Adjusted EPS (1) decreased $0.15 to $0.81 per diluted share Full-year 2024 outlook of 4.0% - 6.0% growth for
